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Abstract
Background: Animal studies demonstrate a clear link between prenatal exposure to glucocorticoids (GC) and
altered offspring brain development. We aim to examine whether prenatal GC exposure programs long-term mental
health in humans.
Methods: Using propensity-score-matching, children prenatally exposed to synthetic glucocorticoids (sGC), n=37,
and controls, n=185, were balanced on important confounders related to sGC treatment - gestational age and pre-
pregnancy BMI. We also used mixed-effects modeling to analyse the entire cohort – matching each sGC case, n=37,
to all possible controls, n=6079, on gestational age and sex. We obtained data from the Northern Finland Birth
Cohort 1986 at four waves – pregnancy, birth, 8 and 16 years. Data on pregnancy and birth outcomes came from
medical records. Mental health was assessed at 8 years by teachers with the Rutter B2 scale, and at 16 years by
parents with the Strengths and Weaknesses of ADHD symptoms and Normal behavior (SWAN) scale and
adolescents by the Youth Self-Report (YSR) scale.
Results: Prenatal sGC treatment was consistently associated with adverse mental health in childhood and
adolescence, as shown by both the propensity-score method and mixed-effects model. Using the propensity-score-
matched subsample, linear multiple regression showed prenatal sGC was significantly linked with general psychiatric
disturbance (B=8.34 [95% CI: .23-16.45]) and inattention (B= .97 [95% CI: .16-1.80]) at 8 years after control for
relevant confounders. Similar findings were obtained at 16 years, but did not reach statistical significance. Mediation
by birthweight/placental weight was not detected.
Conclusions: This study is the first to prospectively investigate the long-term associations between prenatal
exposure to sGC treatment and mental health in children and adolescents. We report an association between
prenatal exposure to sGC and child mental health, supportive of the idea that sGC has a programming effect on the
fetal brain.
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Introduction
Cortisol, a naturally occurring glucocorticoid (GC), plays a
vital role in fetal development [1]. This hormone exerts a wide
range of effects in most regions of the developing brain,
initiating terminal maturation, remodeling of axons and
dendrites, and affecting cell survival [2]. However, sustained
elevation or reduction of GC levels can impair these processes,
and thereby permanently modify brain structure and function
[3], suggesting a role for GC in fetal programming of mental
health. Fetal exposure to elevated levels of maternal cortisol
has been proposed as one mechanism underlying the reported
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connection between prenatal exposure to maternal stress and
symptoms of attention-deficit/hyperactivity disorder (ADHD) in
the offspring [4-6]. ADHD is the most common behavioral
disorder in young people, characterized by inappropriate
inattention, hyperactivity and impulsivity [7,8], and is related to
impairments in all areas of life e.g. social and scholastic
domains [9].
Animal models provide strong evidence that prenatal
exposure to both elevated endogenous maternal GC and
synthetic glucocorticoids (sGC) alter fetal brain development
and consequently impact upon behavior [6,10,11], including
hyperactivity [12] and attention [13]. However, without
experimental evidence in humans the effect cannot be
confirmed. The routine administration of sGC in cases of
threatened pre-term birth offers an opportunity to study whether
prenatal exposure to GC is associated with long-term
programming of behavior in humans in a quasi-experimental
manner.
sGC is commonly administered to pregnant women when
pre-term birth is impending to accelerate fetal lung maturation
and thereby reduce the risk of respiratory distress syndrome,
and neonatal mortality [14]. Yet, very little is known about the
long-term effects of prenatal sGC treatment on child behavior,
including ADHD symptoms. The few existing studies report
inconsistent findings. Some studies report an association
between repeated prenatal sGC treatment and distractibility,
hyperactivity and aggressive behavior [15], as well as attention
problems [16] in young children, but others do not [17-19].
Generally, studies are limited by short follow-up times (young
children only) and mostly examine the impact of repeated
doses of prenatal sGC, and so little is known about the long-
term impact of low/infrequent doses of prenatal sGC exposure
on later child behavior. This is particularly important given that
current guidelines recommend that only a single course of sGC
should be administered (either 2 doses of 12mg of
betamethasone or 4 doses of 6mg of dexamethasone) because
of concerns regarding potential long-term effects of repeated
sGC treatment [20]. One study examined the long-term
association and reported that adults at age 31 who received a
single course of prenatal sGC did not differ on mental health
outcomes from those in the placebo condition [21]. However,
the placebo group in this study received cortisone acetate with
a 70th of sGC potency, and so the impact of sGC from non-
exposure cannot be completely assessed. Further studies are
thus needed to examine this association.
Besides the potential impact on the fetal brain, prenatal
exposure to sGC treatment in humans has been linked with
reduced birth size [22]. Small size at birth, in turn, has been
implicated as a risk factor for child mental health [23]. It is
possible that small birth size, which is a marker of suboptimal
intrauterine conditions, may reflect altered brain development
[23]. Prenatal exposure to maternal stress has also been linked
to reduced birth size [24], with excess maternal GC as a
potential causal mechanism [6]. The placenta, which normally
acts as a barrier to regulate fetal exposure to endogenous
maternal GC (inactivating excess cortisol to cortisone) [25],
may play a key role in GC programming [26]. Prenatal
exposure to sGC and maternal stress have also been
associated with altered placental size [27,28], which in turn has
been linked with child and adolescent mental health [29].
Changes in placental size can affect fetal nutrient and hormone
supply [30], resulting in altered fetal growth and organ
development, including the brain. Thus, it is possible that the
GC-mental health link is mediated by deviation in either birth
size and/or placental size.
To clarify previous inconsistent findings, we examined data
from a large, longitudinal cohort following children and
adolescents. In studies examining prenatal sGC effects on
child mental health, treatment-selection bias is a main issue,
which we address here. It is essential to disentangle the
potential effect of treatment from the conditions precipitating
treatment. Our large dataset enabled us to very accurately
match prenatally sGC exposed (cases) and unexposed
(controls) children on baseline characteristics related to sGC
treatment, by means of propensity-score-matching. However,
an important limitation of propensity-score-matching is that,
particularly in large studies, many unmatched controls are
excluded from analysis, resulting in loss of data which may
reduce the precision of the estimated association between the
treatment and outcome [31]. Thus, we also used the entire
cohort to analyse the data – matching each case to all possible
controls on important confounders. The two matching
procedures allowed us firstly to isolate the impact of prenatal
sGC exposure on mental health from the confounding effects of
treatment, and secondly, to examine the robustness of the
results, thereby addressing important limitations of previous
research. Further, we investigated whether birthweight and
placental weight mediate the association between prenatal
sGC treatment and offspring mental health to gain insight into
the potential causal pathway. This is the first study to
investigate the long-term impact of prenatal sGC treatment
(low/infrequent doses) versus no treatment on mental health,
particularly ADHD symptoms, in childhood (8 years) and again
in adolescence (16 years). We hypothesise that prenatal sGC
treatment will be related to poor mental health outcomes.
Materials and Methods
Participants
The Northern Finland Birth Cohort (NFBC) 1986 recruited
women in early pregnancy with an expected date of delivery
between July 1, 1985 to June 30, 1986; 99% participated.
Prospective data was gathered from pregnancy to child age 16
years. The cohort consists of 9479 births in Oulu and Lapland
provinces. Here, we include N=8954 liveborn singletons with
consent to use their data (exclusions: 226 twins, 6 triplets and
249 without consent).
All pregnant women, literate in Finnish, were consecutively
recruited at their first prenatal health care visit to tax-paid
prenatal health services, which offer high-quality standardized
care used by essentially all women in the country [32]. Women
provided information via structured self-report questionnaires.
Antenatal clinical and birth outcome data were obtained from
maternity health centres and hospital medical records
(completed by midwives during pregnancy and at birth), and
abstracted onto study forms. As the original NFBC 1986
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dataset did not include data on prenatal sGC treatment, we
screened for potential sGC cases by performing a systematic
chart review (see Figure S1).
The cohort was followed-up at child ages 8 years (n=8106;
91% of original sample) and 16 years (n=6934; 77% of original
sample), and focused on child health and well-being. Follow-
ups were carried out using the national population-based
registries, which identify all residents by unique personal
numbers, to obtain current addresses. Thus, participants could
be traced even outside the original geographic area.
The ethics committee of Northern Ostrobotnia Hospital
District approved the study, and both parents and adolescents
gave written informed consent.
Predictor: Prenatal sGC Treatment
In Finland in 1985/86, prenatal sGC treatment was
administered in rare cases (at the discretion of the medical
practitioner) as use of sGC during pregnancy was still
controversial at the time, which explains the relatively few
number of sGC cases in our study. There was no standard
protocol for sGC treatment in the NFBC 1986 cohort, although
caution was taken as only small and infrequent doses were
administered. Dexamethasone (n=33) or betamethasone (n=4)
- the drugs of choice for threatened pre-term birth, were
administered. At 8 and 16 years, n=37 and n=29 cases
respectively were available for analysis. Out of the 37 cases (at
8 years), 13 received a single sGC dose, 23 received 2 doses
and the dose number for 1 case was not recorded. The total
dosage ranged from 10mg to 25mg (the maximum total dosage
equates approximately to a single course of sGC treatment as
recommended by current guidelines). We obtained data on
sGC treatment, number of sGC doses, total sGC dose and the
interval between prenatal sGC exposure and birth (days), from
medical records.
Fetal exposure to GC is regulated by placental 11β-
hydroxysteroid dehydrogenase type 2 (11β-HSD2) – an
enzyme which normally inactivates 50-90% of endogenous
maternal GC [25,33], but does not extensively metabolize sGC.
Placental 11β-HSD2 inactivates only about 2% of
dexamethasone and 7% of betamethasone [34], allowing the
majority of sGC to cross the placenta to exert its intended
therapeutic effect on fetal tissues. In contrast, prednisone (n=2)
and hydrocortisone (n=1) have minimal placental transfer and
so are typically administered to treat maternal medical
conditions (e.g. allergic or inflammatory diseases) and were
excluded from the analyses.
Betamethasone and dexamethasone are long-acting
substances (with biological half-lives ranging between 36 and
54 hours) [35], so it is unlikely that sGC treatment close to the
time of birth could significantly impact fetal brain development
as there would not be sufficient time for the drug to induce
maximum effect. Thus, we excluded cases who had been
exposed to sGC ≤4 days prior birth (n=11).
Potential Mediators: Birthweight and Placental Weight
Birthweight (grams) was measured accurate to ±10g,
immediately after birth by medical personnel. Placentas were
washed with water and then weighed (including membranes
and umbilical cord, cut approximately 5cm from the neonate) to
the nearest gram within 30 minutes after birth, according to
standard protocols [29].
Outcome: Child and Adolescent Mental health
Teachers assessed child behavior at the age of 8 years
using the Rutter B2 scale [36], a well-validated screener for
childhood mental health. Each of the 26 items is rated as either
it ‘certainly applies’ (scored 2), ‘applies somewhat’ (scored 1)
or ‘does not apply’ (scored 0); yielding a total score between 0
to 52. The questionnaire generates three sub-scores: neurotic,
antisocial and inattention-hyperactivity. Additionally, we
examined the core ADHD symptoms individually i.e. inattention
and hyperactivity.
Parents reported adolescent behavior at 16 years using the
Strengths and Weaknesses of ADHD symptoms and Normal
behavior (SWAN) scale [37]. The SWAN consists of 18 items
based on the symptoms of ADHD listed in the DSM-IV (9 items
in the inattention subscale, 9 items in the hyperactive-
impulsivity subscale, and together the 18 items indicate ADHD
combined subtype). As this scale measures both weaknesses
(scored 3, 2, 1) and strengths (scored -1, -2, -3), along with
average behavior (scored 0), it is expected to produce a normal
distribution of behavioral scores, thereby reducing the risk of
over/under identifying ADHD behavior.
Adolescents provided mental health self-reports at 16 years
by completing the Youth Self-Report (YSR) [38] – a widely
used questionnaire, derived from the Child Behavior Check List
(CBCL), for use by 11-18-year-olds. The YSR includes 112
items covering behavioral and emotional problems, which are
scored on a three-point scale (‘certainly applies’, ‘somewhat
applies’ and ‘does not apply’, scored 2, 1 and 0, respectively).
The YSR total problem score taps withdrawal, somatic
complaints, anxiety/depression, thought problems, social
problems, attention problems, delinquent behavior and
aggressive behavior.
Confounders
We considered potential confounders related to sGC
treatment and child mental health which were available in the
cohort. Socio-demographic factors previously associated with
ADHD symptoms were: sex, maternal age (years), maternal
education (either ≥11 years of education or <11 years of
education, coded 0 or 1, respectively) and family structure
(either married/co-habiting or single/widowed/divorced, coded 0
or 1, respectively) [39-41]; the latter three factors were
measured at recruitment. Medical factors previously associated
with child mental health or relevant for this study were:
gestational age [42], total prenatal sGC dose (mg), interval
between prenatal sGC exposure and birth (days), parity
(continuous) [43], pre-pregnancy body mass index (BMI) (pre-
pregnancy weight [kg] / height2 [m2]) (continuous) [32], and
smoking during pregnancy (no/yes, coded 0/1, respectively)
[40]. We obtained data on the main pregnancy complications
related to pre-term birth from hospital records: gestational
hypertension (no/yes), pre-eclampsia (no/yes) and placenta
previa (no/yes).
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Statistical Analysis
We used two analytical strategies to analyse the data: (1)
analysis of the propensity-score-matched subsample by linear
multiple regression, and (2) analysis of the entire sample by
mixed-effects modeling. All main analyses were performed
using SPSS 20.0, while the power analysis was run using
G*Power 3 [44].
Descriptive Analysis
We carried out descriptive analyses of all covariates
potentially associated with sGC treatment, by means of t-test or
chi-square statistics. Further, we examined whether there were
any significant differences between matched cases and
controls (within the propensity-score-matched subsample) by
the covariates by means of t-test or chi-square statistics.
We performed attrition analyses at each follow-up to
determine any differences in socio-demographics, birth
outcomes and mental health outcomes between participants
and non-participants.
Matching Procedure
We used two matching procedures. First, we used
propensity-score-matching [45] to match sGC cases and
controls. The propensity score is the probability of treatment
assignment based on observed baseline covariates. Matching
on the propensity score creates balance, i.e. similarity,
between cases and controls on the distribution of baseline
covariates and thus reduces confounding associated with
receipt of treatment. This matching technique mimics the
randomization procedure prior to treatment allocation in a
Randomized Controlled Trial (RCT). Thus, propensity-score-
matching facilitates estimation of treatment effects using
observational data.
The covariates associated with sGC treatment were included
as predictors in the logistic regression model used to calculate
the propensity scores. The propensity scores were log
transformed to normalize the distribution of the scores. sGC
cases were matched to controls on the logit propensity score,
using “nearest neighbour matching” with a caliper width
(matching range) of ± 0.171402 (0.2 SD of the mean logit of the
propensity score) [46]. We capitalized on our large dataset by
matching each sGC case to 5 controls; ratio matching has
been shown to be advantageous, and the optimum matching is
normally reached with 5 matches to a single case [47]. This
resulted in a sample of 222 children at 8 years (sGC cases,
n=37; controls, n=185) and a sample of 174 adolescents at 16
years (sGC cases, n=29; controls, n=145).
The second matching procedure took full advantage of the
entire cohort by matching each sGC case, n=37, to all possible
controls, n=6079, on gestational age and sex – confounders
selected based on a priori information. Pre-term birth is a well-
known risk factor for poor mental health outcomes [42] and is
associated with gestational complications [48]. There is
evidence that male fetuses are more vulnerable to prenatal
insults [49], and are at an increased risk of psychiatric
disturbance in childhood [41,50]. Thus, by matching on these
known risks, we were able to isolate the impact of prenatal
sGC exposure on mental health from the confounding effects of
pre-term birth and sex.
A “grouping” variable, based on gestational age and sex,
was used to match the cases and controls. There were no sGC
cases born within gestational weeks 41 to 43, therefore the
2229 controls born within those gestational ages could not be
compared with the cases and consequently excluded from all
subsequent analyses. At 8 years, 6116 children were available
for analysis (sGC cases, n=37; controls, n=6079) and by 16
years of age, 5108 adolescents participated (sGC cases, n=29;
controls, n=5079). This analytical strategy allowed us to use
the greatest number of possible controls per case, thereby
enhancing the precision of the analysis by maximizing use of
all the available data [51].
Regression Models
We used linear multiple regression to investigate the
association between prenatal sGC treatment and child mental
health, within the propensity-score-matched subsample.
Prenatal sGC treatment was dichotomized: sGC case (coded
1) and sGC control (coded 0). The mental health scores were
continuous. We adjusted for all potential confounders as shown
by our descriptive analysis or by previous research. We used
Cohen’s f2 as an effect size estimator for the associations.
We used mixed-effects modeling to re-analyse the
association between prenatal sGC and mental health, but here
we used the entire cohort. In this way, we can determine if the
results are replicable or merely due to certain characteristics in
the subsample. This statistical technique is robust in the
analysis of unbalanced data, and thus is suitable here where
there are unequal numbers of cases and controls. In the model,
the predictor (prenatal sGC) and confounders were included as
fixed effects. The “grouping” variable, based on gestational age
and sex, was included as a random effect, thus allowing the
model representing the impact of sGC on mental health to vary
as a function of the group, thereby reducing the confounding
effects of pre-term birth and sex.
Mediation Analysis
We used the bootstrap method [52,53] to evaluate whether
birthweight and placental weight mediated the possible
association between prenatal sGC and mental health, within
the propensity-score-matched subsample. This is a resampling
method which generates accurate confidence intervals to
assess mediation effects. Bootstrapping does not impose any
assumption about the shape of the distribution of the mediation
effect, and thus it has been suggested that it is a more powerful
technique than single sample methods [52,54].
Power Analysis
We performed a post hoc power analysis to determine
whether our study was sufficiently powered to detect any
possible significant impact of sGC treatment, at 8 years and 16
years.
Prenatal Glucocorticoids and Later Mental Health
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Results
Descriptive Analysis
Table S1 shows pregnancy and birth characteristics for the
unmatched cases and controls, available for analysis. Prior to
propensity-score-matching, sGC cases and controls differed
significantly on gestational age, birthweight, and placental
weight. The difference on pre-pregnancy BMI was significant,
p=.04 (based on all treated cases, n=41). As gestational age
and pre-pregnancy BMI precede sGC treatment, these
covariates were included in the propensity-score model.
Table 1 shows pregnancy and birth characteristics for the
propensity-score-matched cases and controls. There were no
significant differences between the matched sGC cases and
controls on any of the socio-demographic or medical factors.
Importantly, there were no significant differences on gestational
age and pre-pregnancy BMI, nor on the mean logit propensity
score (case mean=-4.35; control mean=-4.36; p=.96) –
indicating balance between cases and controls on treatment-
associated confounders.
Table S2 shows the attrition analyses among sGC cases
from birth to 8 years, and from 8 years to 16 years. There were
no significant differences by socio-demographics and birth
outcomes between the participants and non-participants at 8
years. Similarly, attrition was not characterised by any
significant differences from childhood to adolescence by socio-
demographics, birth outcomes and mental health (at 8 years).
While all the sGC cases were hospitalized, only one sGC
case experienced one of the main pregnancy complications
related to pre-term birth (gestational hypertension, pre-
eclampsia or placenta previa). This single case did not
significantly impact upon the mean mental health scores, and
therefore was included in all analyses. Out of the controls,
approximately 15% were hospitalized and 9% experienced the
main pregnancy complications related to pre-term birth.
Regression Models
Table 2 shows the linear multiple regression results for the
association between prenatal sGC treatment and mental health
outcomes in children and adolescents, controlled for sex,
birthweight, placental weight, socio-demographic factors
(maternal age, education and family structure), and medical
factors (total prenatal sGC dose, interval between prenatal
sGC exposure and birth (days), parity and smoking during
pregnancy). There were significant associations between
prenatal sGC treatment and the total Rutter and inattention
scores, at 8 years. The effect sizes for the total Rutter,
inattention-hyperactivity, inattention and antisocial scores were
moderate, while the association for the hyperactivity score
showed a large effect size. Similar to the results at 8 years, we
found consistent significant associations between prenatal sGC
treatment and each of the outcome scores at 16 years;
however, these did not reach statistical significance.
Table 3 shows that the mixed-effects model produced very
similar results to the first analysis. Prenatal sGC treatment was
significantly associated with the total Rutter and inattention
scores at 8 years, and was consistently associated with higher
scores on all other outcomes at 8 and 16 years. Additionally,
this method revealed neurotic scores were also elevated
among sGC cases in comparison to controls at 8 years.
Mediation Analysis
The bootstrap method showed that there were no significant
indirect effects of birthweight (e.g. for total Rutter score,
bootstrap estimate=.67, percentile 95% CI=-1.33-3.00) or
placental weight (e.g. for total Rutter score, bootstrap
estimate=.24, percentile 95% CI=-1.07-2.00) on the sGC-
mental health pathway. Thus, we did not find evidence for
mediation by birthweight or placental weight.
Power Analysis
The post hoc power analysis showed that the study had
sufficient power to detect significant differences at 8 years (e.g.
for total Rutter score model, 1-β=.80, with an effect size f2=.23
and p=.05), but was under-powered at 16 years (e.g. for
combined ADHD score model, 1-β=.39, with an effect size f2=.
11 and p=.05).
Discussion
This study is the first to explore the long-term associations
between prenatal exposure to sGC treatment and mental
health in childhood and adolescence. We found that both
children and adolescents prenatally exposed to sGC scored
consistently higher on internationally validated screening
instruments of mental health, by teacher, parental and self-
reports, than controls. The propensity-score-matched
subsample showed that prenatal exposure to sGC treatment
was significantly associated with the total Rutter and inattention
scores in childhood, independent of relevant confounders –
sex, birthweight, placental weight, socio-demographic factors
and medical factors. Past studies have in particular found it
challenging to disentangle the effect of prenatal sGC on mental
health from pre-term birth, which is associated with both sGC
treatment and child mental health. Through propensity-score-
matching, cases and controls were balanced, i.e. matched, on
gestational age and pre-pregnancy BMI, and so we were able
to isolate the impact of prenatal sGC on mental health from
these treatment-associated confounders. Therefore, our
findings suggest that prenatal sGC is a potential programming
agent of child mental health, rather than a mere
epiphenomenon. We examined the robustness of our findings
by testing the association using the entire cohort by means of
mixed-effects modeling. We found very similar results using the
entire sample compared with the subsample, providing further
evidence that our results are unlikely to be affected by
confounding.
We set out to examine the potential long-term association
between prenatal sGC exposure and mental health, and
therefore studied adolescents by way of parental-report specific
for ADHD symptoms and self-report for general mental health.
Given attrition by the 16-year follow-up, only 29 cases
remained for analysis which left our study under-powered at
this point - as confirmed by our power analysis. Nonetheless,
the pattern of associations at 16 years was consistent with the
findings reported at 8 years.
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Table 1. Pregnancy and birth characteristics for the sGC casesa (n=37) and matched controls (n=185); 1:5 matching ratio,
matched on logit of propensity score.
Characteristic Mean ± SD or n (%)  
 Case Control P
Pregnancy    
Maternal age (years) 29.2 ± 5.0 27.6 ± 5.2 .10
Family structure   .37
Married/co-habiting 36 (97.3) 173 (93.5)  
Single/widowed/divorced 1 (2.7) 12 (6.5)  
Education (years)   .92
<11 10 (31.3) 54 (32.1)  
≥11 22 (68.8) 114 (67.9)  
Parity   .98
0 11 (29.7) 60 (32.4)  
1 16 (43.2) 76 (41.1)  
2 6 (16.2) 32 (17.3)  
≥ 3 4 (10.8) 17 (9.2)  
Smoking during pregnancy   .17
No 31 (86.1) 137 (75.7)  
Yes 5 (13.9) 44 (24.3)  
Pre-pregnancy BMI 21.1 ± 2.5 20.5 ± 2.6 .22
Pre-pregnancy BMI categories   .44
< 20 14 (37.8) 87 (47.0)  
20-24.99 20 (54.1) 90 (48.6)  
≥ 25 3 (8.1) 8 (4.3)  
Main pregnancy complications – risk for pre-term birth    
Gestational hypertension 0 (.0) 13 (7.1) .23
Pre-eclampsia 1 (5.3) 4 (2.2) .41
Placenta previa 0 (.0) 1 (.5) .65
Total sGC dose (mg) 15.4 ± 4.6   
Interval between prenatal sGC exposure and birth (days)    
6-14 5 (13.5)   
15-23 0 (.0)   
24-32 6 (16.2)   
33-41 8 (21.6)   
41-49 10 (27.0)   
50-58 4 (10.8)   
59-67 2 (5.4)   
≥ 68 2 (5.4)   
Birth    
Sex   .86
Male 19 (51.4) 98 (53.0)  
Female 18 (48.6) 87 (47.0)  
Gestational age at birth (weeks) 37.2 ± 2.0 37.5 ± 2.0 .60
Gestational age categories (weeks)   .90
Pre-term birth (< 37) 10 (27.0) 48 (25.9)  
Term birth (≥ 37) 27 (73.0) 137 (74.1)  
Birthweight (g) 3159 ± 688 3151 ± 636 .95
Birthweight categories (g)   .59
< 2500 6 (16.2) 23 (12.4)  
2500-4499 30 (81.1) 160 (86.5)  
≥ 4500 1 (2.7) 2 (1.1)  
Placental weight (g) 586 ± 139 588 ± 135 .96
Placental weight categories (g)   .90
< 550 14 (37.8) 75 (40.8)  
550-719 17 (45.9) 84 (45.7)  
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Our findings corroborate and extend previous results of
observational studies of high-risk pregnancies in humans,
which have examined the effect of repeat prenatal sGC doses
on child mental health [15,16]. Most previous studies have
used high-risk samples in comparison to normal pregnancies,
making it difficult to differentiate between medical
complications that prompted treatment and the potential effect
of the treatment itself on the outcome. Ours is a community
cohort in which both controls and cases experienced
pregnancy complications and were hospitalized. Out of the
controls, approximately 9% experienced the most common
causes of pre-term birth (gestational hypertension, pre-
eclampsia and placenta previa) and 15% were hospitalized.
Only one case experienced one of the most common causes of
pre-term birth. In this sense, our results are more
generalizable, rather than specific to high-risk sub-groups and
so are unlikely to be affected by confounding of pregnancy
complications.
We were able to examine the impact of fairly low and
infrequent doses of prenatal sGC (the average total dose was
15.4mg and the maximum dosage was approximately equal to
a single course of sGC, according to current guidelines). Given
the concerns raised by use of repeat sGC in pregnancy [14,22]
and the call for longitudinal research [55], it is of public health
interest to study long-term risks associated with exposure at
this low dosage. Our findings suggest that even at low dosages
the fetal brain may be sensitive to sGC. Interestingly, we found
that prenatal sGC had a non-specific effect on child mental
health, as indicated by an association with the total Rutter,
which reflects a range of emotional and behavioral problems,
including ADHD symptoms. A total Rutter score of ≥9 indicates
probable psychiatric disturbance, and so the mean Rutter score
difference of approximately 8 points between cases and
controls reflects clinical significance.
Cortisol may directly impact brain development because
glucocorticoid receptors (GR) and mineralocorticoid receptors
Table 1 (continued).
Characteristic Mean ± SD or n (%)  
 Case Control P
≥ 720 6 (16.2) 25 (13.6)  
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
doi: 10.1371/journal.pone.0081394.t001
Table 2. Linear multiple regression results for the association between prenatal glucocorticoid treatment (casesa, n=37 (at
8y) n=29 (at 16y), and controls balanced on gestational age and pre-pregnancy BMI, by means of logit of propensity score;
1:5 matching ratio) and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb.
Mental Health Prenatal glucocorticoid (GC) treatment (case/control)
 Unadjusted Adjustedb
 B 95% CI for B β P B 95% CI for B β P Cohen’s f2
8-y-olds Rutter (teacher report)          
Total Rutter score 1.07 -.95-3.10 .08 .30 8.34 .23-16.45 .56 .04 .23
Antisocial score .28 -.45-1.00 .05 .45 2.93 -.04-5.9 .54 .05 .20
Neurotic score .11 -.39-.62 .03 .66 1.55 -.55-3.67 .42 .15 .11
Inattention-hyperactivity score .21 -.40-.72 .04 .58 2.16 -.03-4.35 .52 .05 .33
Inattention scorec -.02 -.23-.18 -.02 .81 .97 .16-1.80 .64 .02 .23
Hyperactivity scored .19 -.21-.58 .07 .35 1.19 -.29-2.67 .41 .12 .36
16-y-olds SWAN (parent report)          
Combined ADHD score -1.15 -8.48-6.19 -.03 .76 16.20 -14.65-47.04 .34 .30 .11
Inattention scoree -.53 -4.31-3.24 -.02 .78 9.00 -6.42-24.41 .37 .25 .11
Hyperactivity scoref -.61 -4.60-3.38 -.02 .76 7.20 -9.85-24.26 .27 .41 .10
16-y-olds YSR (self-report)          
YSR Total Problem score 2.10 -4.55-8.74 .05 .53 2.30 -26.43-31.00 .05 .88 .12
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
b. adjusted for sex, birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors (total prenatal sGC dose,
interval between prenatal sGC exposure and birth (days), smoking during pregnancy and parity).
c. score based on Rutter item number 16 (range 0 to 2).
d. score based on sum of Rutter items 1 and 3 (range 0 to 4).
e. score based on sum of 9 SWAN items (range -27 to 27).
f. score based on sum of 9 SWAN items (range -27 to 27).
doi: 10.1371/journal.pone.0081394.t002
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(MR), both of which have a high affinity for GC, are highly
expressed in the fetal brain [56], particularly the hippocampus
[57]. Animal studies have shown that prenatal sGC exert
widespread effects on the developing brain, reducing neuron
proliferation [58], as well as affecting neuron structure and
synapse formation [59]. Prenatal sGC has been linked with
reduced density of hippocampal neurons in the offspring, in
both humans and animals [57,60]. Altered hippocampal
structure in turn has been associated with mental health,
including ADHD [61,62]. A recent study demonstrated that
prenatal sGC was associated with thinner brain cortex in
children, which in turn was linked with affective problems [63].
There is also evidence that prenatal sGC has a long-term
impact on hypothalamic-pituitary-adrenal (HPA) axis reactivity
in term-born children, which may bear significant implications
for stress-related psychiatric disorders [64].
Table 3. Mixed-effects model for the association between prenatal glucocorticoid treatment (casea vs. control, matched for
gestational age and sex) and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb.
Mental health Prenatal glucocorticoid (GC) treatment (case/control)
 Estimates Pair-wise comparisons
 n Means SE 95% CI Mean difference (B) SE 95% CI P
8-y-olds Rutter (teacher report)         
Total Rutter score     8.04 3.34 1.49-14.60 .02
GC control 6059 3.59 .32 2.90-4.28     
GC case 37 11.63 3.33 5.11-18.15     
Antisocial score     2.15 1.12 -.04-4.35 .05
GC control 6065 .75 .11 .50-1.00     
GC case 37 2.90 1.11 .72-5.01     
Neurotic score     2.48 .84 .84-4.12 .00
GC control 6076 .65 .02 .61-.70     
GC case 37 3.13 .83 1.50-4.76     
Inattention-hyperactivity score     1.53 1.01 -.43-3.51 .13
GC control 6069 3.86 .11 3.62-4.09     
GC case 37 5.39 1.00 3.43-7.36     
Inattention scorec     .79 .35 .12-1.47 .02
GC control 6079 .22 .03 .16-.29     
GC case 37 1.01 .34 .34-1.69     
Hyperactivity scored     .74 .73 -.69-2.17 .31
GC control 6075 2.63 .08 2.46-2.81     
GC case 37 3.37 .73 1.95-4.80     
16-y-olds SWAN (parent report)         
Combined ADHD score     13.92 12.83 -11.22-39.06 .28
GC control 4950 -20.23 .86 -22.10- -18.36     
GC case 29 -6.31 12.77 -31.34-18.72     
Inattention scoree     8.42 6.80 -4.91-21.74 .22
GC control 4950 -8.00 .49 -9.05- -6.94     
GC case 29 .42 6.77 -12.85-13.69     
Hyperactivity scoref     5.47 6.99 -8.24-19.17 .43
GC control 4950 -12.22 .38 -13.05- -11.38     
GC case 29 -6.75 6.96 -20.39-6.89     
16-y-olds YSR (self-report)         
YSR Total Problem score     16.39 12.05 -7.24-40.02 .17
GC control 5079 25.52 1.34 22.67-28.36     
GC case 29 41.91 12.03 18.33-65.49     
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
b. adjusted for birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors (total prenatal sGC dose, interval
between prenatal sGC exposure and birth (days), smoking during pregnancy, parity and pre-pregnancy BMI).
c. score based on Rutter item number 16 (range 0 to 2).
d. score based on sum of Rutter items 1 and 3 (range 0 to 4).
e. score based on sum of 9 SWAN items (range -27 to 27).
f. score based on sum of 9 SWAN items (range -27 to 27).
doi: 10.1371/journal.pone.0081394.t003
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We tested the hypothesis that deviation in birthweight or
placental weight would mediate the association between
prenatal exposure to sGC and child mental health. It is possible
that altered birth size and/or placental size, both of which have
been linked to prenatal sGC exposure [22,27] and child mental
health [23,29], would lie on the GC programming pathway.
However, we did not find support for this idea.
As in all longitudinal studies, attrition occurs at every follow-
up and is the main limitation. With a loss of 9 cases by the 16-
year follow-up, our study was under-powered at this point,
which is a likely explanation for non-significant findings at this
age. The NFBC 1986 is a prospective cohort but was not
designed to examine sGC treatment outcomes - we performed
a chart review to identify sGC cases, thus we cannot rule out
the impact of unmeasured confounders. It is not possible to
completely rule out that the observed differences in mental
health scores may be due to the complications of pregnancy
which prompted sGC treatment. However, this seems unlikely
here as both cases and controls experienced pregnancy
complications, and our matching procedures ensured that
cases and controls were balanced on important confounders.
Due to the very small number of sGC cases experiencing
pregnancy complications known to be a risk for pre-term birth
(n=1), we could not study these as sub-groups. Further work is
required to determine the impact of pregnancy complications
on later mental health with larger samples. Finally, sGC cannot
be directly equated to endogenous maternal GC. sGC and
endogenous GC largely bind to different types of steroid
receptors and so may have different biological effects. Despite
these limitations, sGC provides a useful quasi-experimental
model in the absence of direct experimental manipulation in
humans and provides a tentative proof of concept, warranting
further research to better understand the associations and their
underlying mechanisms.
Our study has important strengths. First, we used propensity-
score-matching to account for treatment-selection bias (thereby
partly mimicking an RCT), in particular gestational age and pre-
pregnancy BMI, and so we were able to isolate the effect of the
drug from these two significant confounders associated with
receipt of treatment. Our large dataset enabled us to very
precisely match cases to controls on the logit propensity
scores. Thus the results presented here are not due to pre-
maturity, which its threat would prompt treatment, and is known
to be a risk for poor neurodevelopmental outcomes, including
ADHD [65,66] nor pre-pregnancy BMI which was also
associated with treatment in this sample as well as ADHD
[32,67]. The matched cases and controls were also balanced
on other important confounders, and these confounders were
additionally adjusted for in the main analysis. Thus, we
minimized confounding related to sGC treatment and mental
health as much as possible. Second, we were able to replicate
the results produced from the propensity-score-matched
subsample using the entire cohort by means of mixed-effects
modeling, demonstrating the robustness of our findings. Third,
we used precise case classification (exposed >4 days prior to
delivery) to ensure that the drug had sufficient time to act on
the fetal brain. Studies which do not take exposure time into
consideration e.g. Dalziel et al. (2005) may be more likely to
report null findings as the drug may not have had time to act on
the fetal brain. Fourth, we assessed child and adolescent
mental health via multiple informants and multiple validated
instruments, which strengthen the credibility of the results and
extend previous findings that have relied almost completely on
parental report. Fifth, we address the growing public health
concern regarding side-effects of sGC treatment by studying
the impact of fairly low/infrequent doses of sGC.
In conclusion, the data we present here, originating from a
population-based cohort, is the largest to date and show an
association between prenatal sGC exposure and child mental
health. Further work is necessary to confirm the long-term
associations. By capitalizing on the natural experiment in which
women are treated with sGC, we were able to explore the
hypothesized pathway between fetal glucocorticoid exposure
and later child mental health. The results show that this
pathway merits further scientific research, though it is a
challenge using human studies. While the benefits of prenatal
sGC treatment on the immediate health and survival of the pre-
term neonate are clear, it is also important to consider the long-
term health implications of this drug, including those relating to
mental health. The clinical ramifications of this study call for
close monitoring of children prenatally exposed to sGC in order
to provide support early if mental health problems arise.
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